{
    "organizations": [],
    "uuid": "3e320b3897a8a049107111c347107325599a5a74",
    "author": "",
    "url": "https://www.reuters.com/article/brief-catabasis-pharma-aligns-resources/brief-catabasis-pharma-aligns-resources-to-focus-on-lead-program-edasalonexent-idUSFWN1RU19I",
    "ord_in_thread": 0,
    "title": "BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17, 2018 / 8:09 PM / Updated 11 minutes ago BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent Reuters Staff 1 Min Read \nApril 17 (Reuters) - Catabasis Pharmaceuticals Inc: \n* CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY \n* CATABASIS PHARMACEUTICALS INC - STRATEGIC CORPORATE RESTRUCTURING SUPPORTS GOAL OF ADVANCING EDASALONEXENT TOWARDS POTENTIAL REGISTRATION \n* CATABASIS PHARMACEUTICALS INC - RESTRUCTURING WILL REDUCE COMPANYâ€™S WORKFORCE BY APPROXIMATELY 42% \n* CATABASIS PHARMACEUTICALS INC - ESTIMATES ANNUALIZED SAVINGS OF APPROXIMATELY $3.3 MILLION IN PERSONNEL-RELATED COSTS \n* CATABASIS PHARMACEUTICALS INC - ESTIMATED ONE-TIME SEVERANCE AND RELATED COSTS OF APPROXIMATELY $1.0 MILLION IN Q2 OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-04-17T23:06:00.000+03:00",
    "crawled": "2018-04-17T23:22:32.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharma",
        "aligns",
        "resource",
        "focus",
        "lead",
        "program",
        "edasalonexent",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "catabasis",
        "pharmaceutical",
        "inc",
        "catabasis",
        "pharmaceutical",
        "aligns",
        "resource",
        "focus",
        "lead",
        "program",
        "edasalonexent",
        "treatment",
        "duchenne",
        "muscular",
        "dystrophy",
        "catabasis",
        "pharmaceutical",
        "inc",
        "strategic",
        "corporate",
        "restructuring",
        "support",
        "goal",
        "advancing",
        "edasalonexent",
        "towards",
        "potential",
        "registration",
        "catabasis",
        "pharmaceutical",
        "inc",
        "restructuring",
        "reduce",
        "company",
        "workforce",
        "approximately",
        "catabasis",
        "pharmaceutical",
        "inc",
        "estimate",
        "annualized",
        "saving",
        "approximately",
        "million",
        "cost",
        "catabasis",
        "pharmaceutical",
        "inc",
        "estimated",
        "severance",
        "related",
        "cost",
        "approximately",
        "million",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}